In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must be considered for antibiotic susceptibility pa...
Main Authors: | Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/8/12/1981 |
Similar Items
-
Frequency of extended spectrum β-Lactamase producing Enterobacteriaceae in intensive care units
by: Mirsalehian.A, et al.
Published: (2007-06-01) -
Carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
by: Jann-Tay Wang, et al.
Published: (2015-01-01) -
Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae
by: Keite da Silva Nogueira, et al. -
Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012-2015
by: Chang YT, et al.
Published: (2019-07-01) -
OXA-181 Beta Lactamase is not a Major Mediator of Carbapenem Resistance in Enterobacteriaceae
by: M. Shanthi, et al.
Published: (2013-09-01)